Literature DB >> 20384581

Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells.

Silvia Carloni1, Francesco Fabbri, Giovanni Brigliadori, Paola Ulivi, Rosella Silvestrini, Dino Amadori, Wainer Zoli.   

Abstract

Alterations in tyrosine kinase expression or functionality have been linked to tumor growth, and detailed analysis of tyrosine kinase pathways has led to the development of novel anticancer drugs based on their inhibition. The aim of the present work was to examine the cytotoxicity and cellular alterations correlated with multidrug resistance mechanisms induced by three tyrosine kinase inhibitors, lapatinib, sorafenib and gefitinib. The study was performed on three breast cancer cell lines (BRC-230, MCF-7 and SkBr3). Drug-induced growth inhibition was detected by Sulforhodamine B analysis. Apoptosis, cytosolic calcium alteration, extrusion pump activity and mitochondrial membrane depolarization were assessed by flow cytometry. Drug efflux-related gene expression was analyzed by RT-PCR and drug target protein expression was evaluated by Western Blot. Lapatinib and gefitinib induced a cytotoxic effect and mitochondrial membrane depolarization in BRC-230 and SkBr3 cells, while sorafenib induced apoptosis and a high and rapid dissipation of mitochondrial potential in all cell lines. Moreover, all three drugs produced a rapid cytosolic calcium mobilization from endoplasmic reticulum stores in the investigated cell lines and a strong decrease in multidrug transporter activity in BRC-230 and MCF-7 cells. Mitochondrial membrane depolarization and inhibition of multidrug transporter activity induced by tyrosine kinase inhibitors were independent of cytosolic calcium mobilization. These data suggest that the investigated drugs possess mechanisms of action that are independent of drug target expression, opening up further possibilities for the development of new therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20384581     DOI: 10.2174/156800910791208580

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  6 in total

1.  Combined Menin and EGFR Inhibitors Synergize to Suppress Colorectal Cancer via EGFR-Independent and Calcium-Mediated Repression of SKP2 Transcription.

Authors:  Bryson W Katona; Rebecca A Glynn; Kayla E Paulosky; Zijie Feng; Caroline I Davis; Jian Ma; Corbett T Berry; Katherine M Szigety; Smita Matkar; Yuanyuan Liu; Haoren Wang; Yuan Wu; Xin He; Bruce D Freedman; Donita C Brady; Xianxin Hua
Journal:  Cancer Res       Date:  2019-03-15       Impact factor: 12.701

2.  Sorafenib reverses resistance of gastric cancer to treatment by cisplatin through down-regulating MDR1 expression.

Authors:  Yi-Sheng Huang; Zhi Xue; Hua Zhang
Journal:  Med Oncol       Date:  2015-01-13       Impact factor: 3.064

3.  Combination therapy using oral S-1 and targeted agents against human tumor xenografts in nude mice.

Authors:  Mamoru Nukatsuka; Hitoshi Saito; Fumio Nakagawa; Hiroaki Tsujimoto; Kazuki Sakamoto; Sayaka Tsukioka; Junji Uchida; Mamoru Kiniwa; Takashi Kobunai; Teiji Takechi
Journal:  Exp Ther Med       Date:  2012-02-13       Impact factor: 2.447

4.  HER2 signaling regulates HER2 localization and membrane retention.

Authors:  Jaekwang Jeong; Wonnam Kim; Lark Kyun Kim; Joshua VanHouten; John J Wysolmerski
Journal:  PLoS One       Date:  2017-04-03       Impact factor: 3.240

5.  Identification of lapatinib sensitivity-related genes by integrative functional module analysis.

Authors:  Qi-Hua Yuan; Guodong Liu; Qiuhui Hu; Jingwen Wang; Kaiming Leng
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

6.  CTR9-mediated JAK2/STAT3 pathway promotes the proliferation, migration, and invasion of human glioma cells.

Authors:  Yang Xu; Jiaguo Chen; Gao He; Yuhai Zhang
Journal:  J Clin Lab Anal       Date:  2021-08-08       Impact factor: 2.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.